MedTrace Logo

Pilot Study of Minocycline in Huntington's Disease

NCT00277355 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2013-04-19

Study results available
· View outcomes & findings →

Summary

This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.

Conditions

  • Huntington Disease

Interventions

DRUG

minocycline

Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)

DRUG

Matching placebo

Matching placebo 1 capsule twice daily, 18 months treatment duration.

Sponsors & Collaborators

  • FDA Office of Orphan Products Development

    collaborator FED

  • Merit Cudkowicz

    lead NETWORK

Principal Investigators

  • Merit E. Cudkowicz, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277355 on ClinicalTrials.gov